Viewing nowValsartec 40 mg (Valsartan)
Valsartan 40mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

MFDS item code 201105918 · Approved 2011.08.31 · Insurance code 644913380
Treatment of hypertension, reduction of the risk of death after myocardial infarction, and treatment of heart failure
This medication is used for the treatment of essential hypertension and is also applicable to patients with heart failure who are intolerant to ACE inhibitors. It helps reduce the risk of mortality in patients with left ventricular dysfunction following myocardial infarction. Thus, it is effective for maintaining cardiovascular health and reducing the risk of complications through blood pressure control and improvement of heart function. Therefore, this medication is used for hypertension, certain heart failure conditions, and post-myocardial infarction treatment.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose should then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients being treated with other therapies after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or those on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more per day are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. It should not be used by individuals with a known allergy to this medication or those with severe liver dysfunction, very poor kidney function, or pregnant or breastfeeding women. Caution is required for the elderly or patients with high blood potassium levels or impaired liver function, and dosage adjustment may be necessary. Patients with heart failure or after myocardial infarction may experience changes in kidney function, so renal function must be monitored before and during treatment. This medication lowers blood pressure, which may cause sudden drops in blood pressure leading to dizziness or fainting when first taken; thus, careful observation of the patient's condition is necessary. There is a risk of hyperkalemia, so blood potassium levels should be frequently monitored when taken in conjunction with potassium supplements or potassium-sparing diuretics. Interactions may occur when taken with other antihypertensives, diuretics, or non-steroidal anti-inflammatory drugs (NSAIDs), so consultation with a physician or pharmacist is necessary. Women who are pregnant or planning to become pregnant should consult healthcare professionals before use, and breastfeeding women are recommended to discontinue breastfeeding if taking this medication. Safety and efficacy have not been established in children and adolescents under 18 years old, so it is best not to use this medication in these age groups. In cases of overdose, severe hypotension and decreased consciousness may occur, requiring immediate medical attention. This medication should be kept out of reach of children and should not be transferred to another container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture exposure and be kept in a cool place below 30 degrees Celsius for optimal efficacy.
Yellow oval film-coated tablet
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 40mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.